CCR5, a new target of anti-HIV drugs.
- Author:
Yan-xing HAN
1
;
Jian-dong JIANG
Author Information
1. Laboratory of Virology, Institute of Medicinal Biotechnology, CAMS and PUMC, Beijing 100050, China. hanyanxing@hotmail.com
- Publication Type:Journal Article
- MeSH:
Anti-HIV Agents;
pharmacology;
Antibodies, Monoclonal;
CCR5 Receptor Antagonists;
Drug Design;
HIV Infections;
metabolism;
HIV-1;
drug effects;
Receptors, CCR5;
drug effects;
Receptors, Chemokine;
drug effects
- From:
Acta Academiae Medicinae Sinicae
2003;25(5):635-639
- CountryChina
- Language:Chinese
-
Abstract:
CCR5, a membrane protein on cell surface, is a member of the G protein-coupled receptor superfamily and one of the major co-receptors for HIV-1 infection. The roles of CCR5 in HIV-1 infection have been elucidated since 1996. Because of the biological nature of CCR5, it has became a molecular target for the novel drugs against HIV-1. Antagonists for CCR5 could be grouped as following, chemokine derivatives, small molecule non-peptide compounds, monoclonal antibodies and peptides. The latest progress in this field is reviewed in this article.
